Cargando…

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1

BACKGROUND: The aim of the current study was to investigate the prevalence and clinicopathologic characteristics of ROS1‐rearranged non‐small cell lung cancer (NSCLC) in routine genotypic screening in conjunction with the study of PD‐L1 expression, a biomarker for first‐line treatment decisions. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jongmin, Park, Chan Kwon, Yoon, Hyoung‐Kyu, Sa, Young Jo, Woo, In Sook, Kim, Hyo Rim, Kim, Sue Youn, Kim, Tae‐Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312846/ https://www.ncbi.nlm.nih.gov/pubmed/30475455 http://dx.doi.org/10.1111/1759-7714.12917

Ejemplares similares

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma
por: Mao, Yanjiao, et al.
Publicado: (2017)

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer
por: Rogers, Toni-Maree, et al.
Publicado: (2017)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

EGFR mutations and ROS1 and ALK rearrangements in a large series of non‐small cell lung cancer in South India
por: Tarigopula, Anil, et al.
Publicado: (2020)

Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
por: Yao, Yi, et al.
Publicado: (2018)

Comparison between Immunocytochemistry, FISH and NGS for ALK and ROS1 Rearrangement Detection in Cytological Samples
por: Frankel, Diane, et al.
Publicado: (2022)

Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme
por: Lim, Sun Min, et al.
Publicado: (2015)

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
por: Marinelli, Daniele, et al.
Publicado: (2022)

Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
por: Ekin, Zübeyde, et al.
Publicado: (2021)

Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma
por: Lim, Sun Min, et al.
Publicado: (2017)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies
por: Chang, Xing, et al.
Publicado: (2019)

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
por: Korpanty, Grzegorz J., et al.
Publicado: (2014)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Mouse Model for ROS1-Rearranged Lung Cancer
por: Arai, Yasuhito, et al.
Publicado: (2013)

Clinicopathological characteristics with EGFR, ALK, ROS1 genetic alternation and prognostic analysis of primary lymphoepithelioma-like carcinoma
por: Shen, Yinchen, et al.
Publicado: (2019)

Clinical characteristics of non‐small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions
por: Liu, Qinghua, et al.
Publicado: (2022)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
por: Ogura, Hayato, et al.
Publicado: (2017)

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial
por: Shaw, Alice T., et al.
Publicado: (2017)

Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives
por: Kim, Sue Youn, et al.
Publicado: (2022)

Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature
por: Zhu, You-cai, et al.
Publicado: (2016)

Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients
por: Novaes, Lázaro Antonio Campanha, et al.
Publicado: (2021)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Multiple cerebral infarctions in ROS1‐rearranged lung adenocarcinoma
por: Ikushima, Hiroaki, et al.
Publicado: (2021)

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology
por: Patil, Tejas, et al.
Publicado: (2022)

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
por: Desai, Arpita, et al.
Publicado: (2016)

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014)

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors
por: Leonetti, Alessandro, et al.
Publicado: (2020)

Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1(G2032R) and ALK(G1202R)
por: Liu, Siming, et al.
Publicado: (2023)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
por: Begum, Parvin, et al.
Publicado: (2022)

Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach
por: Yoon, Hyun Jung, et al.
Publicado: (2015)

Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations
por: Wang, H.-Y., et al.
Publicado: (2022)

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
por: Ye, Mingxiang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bvocnds3ftfv7mr22hkfrr2iud